Search CommunityWalk:


MedImmune, LLC.

One MedImmune Way
Gaithersburg, MD, USA

Category: Biotechnology/Biopharmaceutical - Vaccines

Used in the following map:

Maryland Biotech Industry Map

MedImmune, LLC. (formerly Molecular Vaccines, Inc.) is a biotechnology company, focused on the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. It was established in 1988 as Molecular Vaccines, Inc. It is a wholly owned subsidiary of AstraZeneca plc.

MedImmune aims to deliver several promising new biologics to the market through cutting-edge technology by accelerating the development of novel antibody or antibody-like therapeutic and preventive medicines. The company is looking to engineer novel properties, such as effector function improvement, into antibodies to enhance their potency; exploring the possibility of generating long-lasting antibody therapy so that dosing frequency can be reduced; developing bi-specific antibodies, polyspecific antibodies, or polyclonal antibodies to target multiple disease mediators to increase drug efficacy while maintaining an appropriate safety profile. The company uses technologies such as antibody engineering, cell culture production, live viral vaccines, reverse genetics, and virus-like particle technology.

MedImmune's pipeline include: Anti-Ang2 for oncology, MEDI-570 for systemic lupus erythematosus, PIV3 vaccine for lower respiratory tract disease caused by PIV3, Motavizumab nti-RSV humanized IgG1 MAb, MEDI-578 for the treatment of pain, anti-CD19 MAb or MEDI-551 for the treatment of Systemic sclerosis(scleroderma), MEDI-575 for the treatment of advanced solid tumors, etc. It's Synagis® (palivizumab) is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV disease.

MedImmune has research and development collaborations with Amgen Inc, Immune Design Co., DeveloGen AG, Medarex, Inc., Abbott, BioWa, Inc, Catalyst Biosciences, Human Genome Sciences (HGSI), SBI Biotech, and Trellis Biosciences.